Rapid Ebolavirus Triage Test Developed
By LabMedica International staff writers Posted on 25 Feb 2015 |
Image: The Idylla cartridge fully automated, molecular diagnostics system (Photo courtesy of Biocartis).
A Rapid Ebolavirus Triage Test is designed to enable healthcare workers, even in challenging environments, to test blood samples and aims at providing accurate and fast diagnosis of Ebola. The test is designed to offer a unique combination of speed, sensitivity, accuracy and ease-of-use required for outbreaks where time is of the essence.
The test uses 0.2 mL blood that is added directly to the Idylla cartridge, which contains all necessary reagents on board for performing the analysis on Biocartis (Mechelen, Belgium) fully automated, molecular diagnostics system. A complete analysis of the sample takes around 90 minutes and can be operated by healthcare professional in most settings, including in the field, making the test ideal for use in regions with limited infrastructure.
The Rapid Ebola Virus Triage Test was developed in association with Janssen Diagnostics (Beerse, Belgium) and the Institute for Tropical Medicine (Antwerp, Belgium) for its Idylla system, a fully automated molecular diagnostic platform that is CE-IVD marked in Europe. The company believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the USA, Biocartis has now registered for field-testing in West Africa to gather additional clinical evidence for the test performance.
Rudi Pauwels, PhD, Biocartis' Chief Executive Officer commented, “This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed healthcare professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world. One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting.”
Related Links:
Biocartis
Janssen Diagnostics
Belgian Institute for Tropical Medicine
The test uses 0.2 mL blood that is added directly to the Idylla cartridge, which contains all necessary reagents on board for performing the analysis on Biocartis (Mechelen, Belgium) fully automated, molecular diagnostics system. A complete analysis of the sample takes around 90 minutes and can be operated by healthcare professional in most settings, including in the field, making the test ideal for use in regions with limited infrastructure.
The Rapid Ebola Virus Triage Test was developed in association with Janssen Diagnostics (Beerse, Belgium) and the Institute for Tropical Medicine (Antwerp, Belgium) for its Idylla system, a fully automated molecular diagnostic platform that is CE-IVD marked in Europe. The company believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak. After testing of synthetic virus samples in Belgium and the USA, Biocartis has now registered for field-testing in West Africa to gather additional clinical evidence for the test performance.
Rudi Pauwels, PhD, Biocartis' Chief Executive Officer commented, “This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed healthcare professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world. One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting.”
Related Links:
Biocartis
Janssen Diagnostics
Belgian Institute for Tropical Medicine
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia